Monopar Therapeutics (MNPR) Return on Capital Employed (2018 - 2025)

Monopar Therapeutics has disclosed Return on Capital Employed across 7 years of filings, most recently posting 12.57% for Q3 2025.

• Return on Capital Employed for Q3 2025 came in at 12.57%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 12.57% (changed N/A YoY), and the FY2024 annual result was 54.56%, down 11183.0% from the prior year.
• Return on Capital Employed came in at 12.57% for Q3 2025 at Monopar Therapeutics, up from 18.57% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 12.57% in Q3 2025 to a low of 131.32% in Q3 2023.
• The 4-year median for Return on Capital Employed is 68.1% (2022), against an average of 69.73%.
• Across the five-year window, Return on Capital Employed tumbled 328 bps in 2021 and sank 5680 bps in 2023, its largest moves.
• Monopar Therapeutics' Return on Capital Employed stood at 45.78% in 2021, then tumbled by 115 bps to 98.41% in 2022, then slumped by 33 bps to 131.32% in 2023, then surged by 90 bps to 12.57% in 2025.
• The last three Return on Capital Employed figures came in at 12.57% (Q3 2025), 18.57% (Q2 2025), and 131.32% (Q3 2023), per Business Quant data.